Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Hidemitsu KurosawaAkihiko TanizawaHideki MuramatsuChikako TonoAkihiro WatanabeHaruko ShimaMasaki ItoYuki YuzaKazuko HamamotoNoriko HottaMasahiko OkadaAkiko Moriya SaitoAtsushi ManabeShuki MizutaniSouichi AdachiKeizo HoribeEiichi IshiiHiroyuki ShimadaPublished in: Pediatric blood & cancer (2018)
This retrospective study represents the first series of children and adolescents in whom sequential use of imatinib followed by 2G-TKIs was reported. These data provide useful insights into the selection of 2G-TKIs as first-line treatment for children and adolescents with CP-CML.